High molecular response rate of polycythemia vera patients treated with pegylated interferon α-2a

被引:187
作者
Kiladjian, Jean-Jacques
Cassinat, Bruno
Turlure, Pascal
Cambier, Nathalie
Roussel, Murielle
Bellucci, Sylvia
Menot, Marie-Laurence
Massonnet, Gerald
Dutel, Jean-Luc
Ghomari, Kamel
Rousselot, Philippe
Grange, Marie-Jose
Chait, Yasmina
Vainchenker, William
Parquet, Nathalie
Abdelkader-Aljassem, Lina
Bernard, Jean-Francois
Rain, Jean-Didier
Chevret, Sylvie
Chomienne, Christine
Fenaux, Pierre
机构
[1] Hop Avicenne, APHP, Serv Hematol Clin, F-93000 Bobigny, France
[2] Univ Paris 13, Paris, France
[3] Hop St Louis, Hop Paris, APHP, Unite Biol Cellulaire, Paris, France
[4] CHU Dupuytren, Serv Hematol, Limoges, France
[5] CHU Lille, Hop Huriez, Serv Malad Sang, F-59037 Lille, France
[6] Hop Lariboisiere, APHP, Serv Hematol, F-75475 Paris, France
[7] CH Beauvais, Serv Hematol, Beauvais, France
[8] Hop Bichat Claude Bernard, APHP, F-75877 Paris, France
[9] CH Versailles, Serv Hematol, Versailles, France
[10] CH Montfermeil, Serv Hematol, Montfermeil, France
[11] Inst Gustave Roussy, INSERM, U790, Villejuif, France
[12] Hop St Louis, APHP, Paris, France
[13] CH Chartres, Serv Hematol, Chartres, France
[14] Hop St Louis, APHP, Dept Biostat & Informat Med, Paris, France
关键词
D O I
10.1182/blood-2006-03-009860
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
V617F JAK2 mutation is a reliable molecular marker of polycythemia vera (PV), potentially useful to monitor the effect of treatments in this disease. In a phase 2 study of pegylated (peg) IFN-alpha-2a in PV, we performed prospective sequential quantitative evaluation of the percentage of mutated JAK2 allele (%V617F) by real-time polymerase chain reaction (PCR). The %V617F decreased in 24 (89%) of 27 treated patients, from a mean of 49% to a mean of 27% (mean decrease of 44%; P <.001), and no evidence for a plateau was observed. In one patient, mutant JAK2 was no longer detectable after 12 months. In 3 patients homozygous for the mutation, reappearance of 50% of wildtype allele was observed during treatment. The results seem to confirm the gets the malignant clone in PV and show that %V617F assessment using a quantitative method may provide the first tool to monitor minimal residual disease in PV. This trial was registered at www. clinicaltrials.gov as #NCT00241241.
引用
收藏
页码:2037 / 2040
页数:4
相关论文
共 17 条
[1]   Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia [J].
Alvarado, Y ;
Cortes, J ;
Verstovsek, S ;
Thomas, D ;
Faderl, S ;
Estrov, Z ;
Kantarjian, H ;
Giles, FJ .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (01) :81-86
[2]   Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [J].
Baxter, EJ ;
Scott, LM ;
Campbell, PJ ;
East, C ;
Fourouclas, N ;
Swanton, S ;
Vassiliou, GS ;
Bench, AJ ;
Boyd, EM ;
Curtin, N ;
Scott, MA ;
Erber, WN ;
Green, AR .
LANCET, 2005, 365 (9464) :1054-1061
[3]   Treating cancer with PEG intron - Pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation [J].
Bukowski, RM ;
Tendler, C ;
Cutler, D ;
Rose, E ;
Laughlin, MM ;
Statkevich, P .
CANCER, 2002, 95 (02) :389-396
[4]   Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis [J].
James, C ;
Delhommeau, F ;
Marzac, C ;
Teyssandier, I ;
Le Couédic, JP ;
Giraudier, S ;
Roy, L ;
Saulnier, P ;
Lacroix, L ;
Maury, S ;
Tulliez, M ;
Vainchenker, W ;
Ugo, V ;
Casadevall, N .
LEUKEMIA, 2006, 20 (02) :350-353
[5]   A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera [J].
James, C ;
Ugo, V ;
Le Couédic, JP ;
Staerk, J ;
Delhommeau, F ;
Lacout, C ;
Garçon, L ;
Raslova, H ;
Berger, R ;
Bennaceur-Griscelli, A ;
Villeval, JL ;
Constantinescu, SN ;
Casadevall, N ;
Vainchenker, W .
NATURE, 2005, 434 (7037) :1144-1148
[6]   Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha [J].
Jones, AV ;
Silver, RT ;
Waghorn, K ;
Curtis, C ;
Kreil, S ;
Zoi, K ;
Hochhaus, A ;
Oscier, D ;
Metzgeroth, G ;
Lengfelder, E ;
Reiter, A ;
Chase, AJ ;
Cross, NCP .
BLOOD, 2006, 107 (08) :3339-3341
[7]   A gain-of-function mutation of JAK2 in myeloproliferative disorders [J].
Kralovics, R ;
Passamonti, F ;
Buser, AS ;
Teo, S ;
Tiedt, R ;
Passweg, JR ;
Tichelli, A ;
Cazzola, M ;
Skoda, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (17) :1779-1790
[8]  
Langer C, 2005, HAEMATOLOGICA, V90, P1333
[9]   Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis [J].
Levine, RL ;
Wadleigh, M ;
Cools, J ;
Ebert, BL ;
Wernig, G ;
Huntly, BJP ;
Boggon, TJ ;
Wlodarska, L ;
Clark, JJ ;
Moore, S ;
Adelsperger, J ;
Koo, S ;
Lee, JC ;
Gabriel, S ;
Mercher, T ;
D'Andrea, A ;
Fröhling, S ;
Döhner, K ;
Marynen, P ;
Vandenberghe, P ;
Mesa, RA ;
Tefferi, A ;
Griffin, JD ;
Eck, MJ ;
Sellers, WR ;
Meyerson, M ;
Golub, TR ;
Lee, SJ ;
Gilliland, DG .
CANCER CELL, 2005, 7 (04) :387-397
[10]  
Massaro P, 1997, AM J HEMATOL, V56, P126, DOI 10.1002/(SICI)1096-8652(199710)56:2<126::AID-AJH10>3.3.CO